These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31737909)

  • 1. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
    Silberstein SD; Shrewsbury SB; Hoekman J
    Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD; Kori SH
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
    Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
    Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.
    Bekan G; Tfelt-Hansen P
    Headache; 2016 Oct; 56(9):1482-1491. PubMed ID: 27595607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral dihydroergotamine for therapy-resistant migraine attacks in children.
    Hämäläinen ML; Hoppu K; Santavuori PR
    Pediatr Neurol; 1997 Feb; 16(2):114-7. PubMed ID: 9090684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
    Morren JA; Galvez-Jimenez N
    Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
    Kelley NE; Tepper DE
    Headache; 2012 Jan; 52(1):114-28. PubMed ID: 22211870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
    Winner P; Ricalde O; Le Force B; Saper J; Margul B
    Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.